Early treatment with high-efficacy MS drugs cut the risk of relapse, but not disability progression independent of relapse ...
A single silent MRI lesion may warrant earlier treatment escalation in RRMS, with escalation linked to a lower risk of future ...
A major international Phase III clinical trial, led by Queen Mary University of London, has found that ocrelizumab—a medication already prescribed to some patients with MS—significantly slows ...
New research adds to evidence of an underrecognized link between the treatment of multiple sclerosis (MS) with immunomodulatory therapy and the subsequent development of thyroid eye disease (TED), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results